vs
ADMA BIOLOGICS, INC.（ADMA）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是ADMA BIOLOGICS, INC.的5.8倍（$805.5M vs $139.2M）。ADMA BIOLOGICS, INC.净利率更高（35.5% vs 19.1%，领先16.4%）。NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs 18.4%）。NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $34.6M）。过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 25.0%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
ADMA vs NBIX — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $805.5M |
| 净利润 | $49.4M | $153.7M |
| 毛利率 | 63.8% | 97.8% |
| 营业利润率 | 45.1% | 26.2% |
| 净利率 | 35.5% | 19.1% |
| 营收同比 | 18.4% | 28.3% |
| 净利润同比 | -55.9% | 49.1% |
| 每股收益（稀释后） | $0.20 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $139.2M | $805.5M | ||
| Q3 25 | $134.2M | $794.9M | ||
| Q2 25 | $122.0M | $687.5M | ||
| Q1 25 | $114.8M | $572.6M | ||
| Q4 24 | $117.5M | $627.7M | ||
| Q3 24 | $119.8M | $622.1M | ||
| Q2 24 | $107.2M | $590.2M | ||
| Q1 24 | $81.9M | $515.3M |
| Q4 25 | $49.4M | $153.7M | ||
| Q3 25 | $36.4M | $209.5M | ||
| Q2 25 | $34.2M | $107.5M | ||
| Q1 25 | $26.9M | $7.9M | ||
| Q4 24 | $111.9M | $103.1M | ||
| Q3 24 | $35.9M | $129.8M | ||
| Q2 24 | $32.1M | $65.0M | ||
| Q1 24 | $17.8M | $43.4M |
| Q4 25 | 63.8% | 97.8% | ||
| Q3 25 | 56.3% | 98.2% | ||
| Q2 25 | 55.1% | 98.4% | ||
| Q1 25 | 53.2% | 98.4% | ||
| Q4 24 | 53.9% | 98.5% | ||
| Q3 24 | 49.8% | 98.7% | ||
| Q2 24 | 53.6% | 98.4% | ||
| Q1 24 | 47.8% | 98.5% |
| Q4 25 | 45.1% | 26.2% | ||
| Q3 25 | 38.0% | 30.1% | ||
| Q2 25 | 35.1% | 21.2% | ||
| Q1 25 | 30.4% | 4.1% | ||
| Q4 24 | 32.6% | 22.6% | ||
| Q3 24 | 33.1% | 29.5% | ||
| Q2 24 | 36.6% | 24.6% | ||
| Q1 24 | 26.7% | 19.3% |
| Q4 25 | 35.5% | 19.1% | ||
| Q3 25 | 27.1% | 26.4% | ||
| Q2 25 | 28.1% | 15.6% | ||
| Q1 25 | 23.4% | 1.4% | ||
| Q4 24 | 95.2% | 16.4% | ||
| Q3 24 | 30.0% | 20.9% | ||
| Q2 24 | 29.9% | 11.0% | ||
| Q1 24 | 21.7% | 8.4% |
| Q4 25 | $0.20 | $1.49 | ||
| Q3 25 | $0.15 | $2.04 | ||
| Q2 25 | $0.14 | $1.06 | ||
| Q1 25 | $0.11 | $0.08 | ||
| Q4 24 | $0.45 | $1.00 | ||
| Q3 24 | $0.15 | $1.24 | ||
| Q2 24 | $0.13 | $0.63 | ||
| Q1 24 | $0.08 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $713.0M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $3.3B |
| 总资产 | $624.2M | $4.6B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
| Q4 25 | $87.6M | $713.0M | ||
| Q3 25 | $61.4M | $340.2M | ||
| Q2 25 | $90.3M | $264.0M | ||
| Q1 25 | $71.6M | $194.1M | ||
| Q4 24 | $103.1M | $233.0M | ||
| Q3 24 | $86.7M | $349.1M | ||
| Q2 24 | $88.2M | $139.7M | ||
| Q1 24 | $45.3M | $396.3M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $3.3B | ||
| Q3 25 | $431.2M | $3.0B | ||
| Q2 25 | $398.3M | $2.7B | ||
| Q1 25 | $373.4M | $2.5B | ||
| Q4 24 | $349.0M | $2.6B | ||
| Q3 24 | $231.9M | $2.7B | ||
| Q2 24 | $188.3M | $2.5B | ||
| Q1 24 | $153.7M | $2.4B |
| Q4 25 | $624.2M | $4.6B | ||
| Q3 25 | $568.7M | $4.3B | ||
| Q2 25 | $558.4M | $3.9B | ||
| Q1 25 | $510.6M | $3.7B | ||
| Q4 24 | $488.7M | $3.7B | ||
| Q3 24 | $390.6M | $3.5B | ||
| Q2 24 | $376.4M | $3.3B | ||
| Q1 24 | $350.9M | $3.5B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $386.0M |
| 自由现金流率自由现金流/营收 | 24.8% | 47.9% |
| 资本支出强度资本支出/营收 | 0.8% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.72× | 2.53× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $743.9M |
8季度趋势，按日历期对齐
| Q4 25 | $35.6M | $388.4M | ||
| Q3 25 | $13.3M | $227.5M | ||
| Q2 25 | $21.1M | $102.0M | ||
| Q1 25 | $-19.7M | $64.8M | ||
| Q4 24 | $50.2M | $242.5M | ||
| Q3 24 | $25.0M | $158.0M | ||
| Q2 24 | $45.6M | $64.6M | ||
| Q1 24 | $-2.2M | $130.3M |
| Q4 25 | $34.6M | $386.0M | ||
| Q3 25 | $-1.1M | $214.3M | ||
| Q2 25 | $18.7M | $89.5M | ||
| Q1 25 | $-24.4M | $54.1M | ||
| Q4 24 | $47.5M | $235.2M | ||
| Q3 24 | $24.0M | $149.9M | ||
| Q2 24 | $43.6M | $53.0M | ||
| Q1 24 | $-4.6M | $119.1M |
| Q4 25 | 24.8% | 47.9% | ||
| Q3 25 | -0.8% | 27.0% | ||
| Q2 25 | 15.3% | 13.0% | ||
| Q1 25 | -21.2% | 9.4% | ||
| Q4 24 | 40.4% | 37.5% | ||
| Q3 24 | 20.0% | 24.1% | ||
| Q2 24 | 40.7% | 9.0% | ||
| Q1 24 | -5.6% | 23.1% |
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 1.7% | ||
| Q2 25 | 2.0% | 1.8% | ||
| Q1 25 | 4.1% | 1.9% | ||
| Q4 24 | 2.3% | 1.2% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 1.9% | 2.0% | ||
| Q1 24 | 2.9% | 2.2% |
| Q4 25 | 0.72× | 2.53× | ||
| Q3 25 | 0.36× | 1.09× | ||
| Q2 25 | 0.62× | 0.95× | ||
| Q1 25 | -0.73× | 8.20× | ||
| Q4 24 | 0.45× | 2.35× | ||
| Q3 24 | 0.70× | 1.22× | ||
| Q2 24 | 1.42× | 0.99× | ||
| Q1 24 | -0.12× | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
